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Chemotherapy has been anecdotally related to aneurysm growth, but no correlation has been noted to date for localized
transarterial chemoembolization. We present the case of a 64-year-old man with clearly documented accelerated aortic
and iliac artery aneurysm dilation after two rounds of transarterial chemoembolization for hepatocellular carcinoma.
Given the large size with rapid growth of his aneurysms and inability to be listed for transplant consideration before
repair, he was offered endovascular repair and was successfully treated. (J Vasc Surg Cases 2015;1:65-7.)Anecdotal reports have demonstrated an association
between chemotherapy and accelerated aneurysmal
growth.1,2 However, such a report has not been noted
related to transarterial chemoembolization (TACE). Local-
ized TACE therapy requires signiﬁcantly lower doses of the
chemotherapeutic agent, theoretically reducing the sys-
temic effects. We report the ﬁrst clearly documented case
of signiﬁcant, rapid aneurysmal dilatation after TACE.
The patient consented to publication.
CASE REPORT
A 64-year-old Caucasian man was referred to our clinic for
evaluation of aortoiliac aneurysmal disease identiﬁed during
workup for a liver transplant. The patient’s medical history was sig-
niﬁcant for hepatocellular carcinoma (HCC) secondary to hepatitis
C, portal hypertension, chronic obstructive pulmonary disease, and
a resolved hepatitis B infection. He received treatment with riba-
virin and interferon for hepatitis C, resulting in an undetectable
viral load for 11 months leading up to his presentation. Of note,
he had no prior or family history of aneurysmal diseases or
vasculitides.
On initial magnetic resonance imaging during the HCC
workup, a noninﬂammatory infrarenal aneurysm measuring
3.9 cm was identiﬁed in November 2013, with a right common
iliac artery (RCIA) aneurysm measuring 3.3 cm and a left common
iliac artery (LCIA) measuring 2.3 cm (Fig 1).
Three rounds of TACE were performed over the course of
5 months while the patient was being evaluated for liver transplan-
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South Jordan, Utah) was delivered through the right hepatic ar-
tery. Follow-up magnetic resonance imaging in April 2014
demonstrated rapid growth of the aneurysms, with the infrarenal
aorta measuring 4.1 cm, the RCIA measuring 3.6 cm, and the
LCIA measuring 2.8 cm (Fig 2).
During round two of TACE, doxorubicin (50 mg), lipiodol
(1 mL), and LC Beads (AngioDynamics, Queensbury, NY) were
administered to the right hepatic lobe. Computed tomography
angiography imaging in June 2014 revealed progressive aneu-
rysmal dilatation, with measurements of the infrarenal aorta at
4.8 cm, RCIA at 4.3 cm, and the LCIA at 3.3 cm (Fig 3).
The patient was offered endovascular repair of the aneurysm
given the signiﬁcant growth, the size of the aneurysm, and the
transplant committee’s decision to exclude the patient for liver
transplantation secondary to the aneurysms. After his third
TACE procedure using lipiodol (10 mL) as the sole agent, the pa-
tient elected to undergo an endovascular repair.
Off-label techniques, as previously described, were used to
perform successful exclusion of the aneurysm, with bilateral hypo-
gastric artery preservation, and he was discharged home on postop-
erative day 2 without incident.3,4
DISCUSSION
This is the ﬁrst documented case of accelerated CIA
aneurysm growth after TACE treatment. TACE is an
accepted treatment for unresectable HCC.5-7 The pro-
cedure involves gaining access to the hepatic arteries
for targeted chemotherapy, theoretically allowing
much lower doses of chemotherapeutic agents to be
used with little to no systemic inﬂuence of the drug. He-
patic artery aneurysms developing after TACE have
been reported, hypothesized to form secondary to
trauma to vessels during the procedure or as a side effect
of the chemotherapy itself, but no known literature has
documented iliac aneurysmal growth rates after
TACE.8,9
Although the growth rate of CIA aneurysms is debated,
the maximum reported growth rate in the literature is
deﬁned as 0.32 cm/y.10,11 Our patient presented with
signiﬁcantly greater growth. The RCIA and LCIA grew
1.0 cm during a period of just 7 months, and 0.7 cm and65
Fig 1. Magnetic resonance imaging of the abdomen and pelvis,
November 2013.
Fig 2. Magnetic resonance imaging abdomen and pelvis,
April 2014.
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TACE. Aneurysmal disease as a result of chemotherapy is
debated, with a recent report demonstrating no association
between aortic aneurysm growth and chemotherapy.12CONCLUSIONS
Despite this study, there remains a broadly held
concern regarding the effects of these cytotoxic agents
Fig 3. Computed tomography angiography of the abdomen and
pelvis, June 2014.
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would otherwise be considered. There is no prevailing
explanation for aneurysmal growth with chemotherapy
use; however, some have questioned altered generation
of DNA, collagen and elastin, release of inﬂammatory
markers, and disturbance in smooth muscle prolifera-
tion.12 In theory, TACE is a localized treatment and
should not have systemic effects, as are believed to be
seen with other cytotoxic treatments, but this ﬁrst docu-
mented incidence indicates a need for further review and
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